NCT04727775

Brief Summary

Retrospective Non-Randomized Analytical Cohort Study of Completed SARS-CoV2 COVID19 Cases

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
150

participants targeted

Target at P50-P75 for all trials

Timeline
Completed

Started Dec 2020

Typical duration for all trials

Geographic Reach
1 country

2 active sites

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

December 1, 2020

Completed
2 months until next milestone

First Submitted

Initial submission to the registry

January 22, 2021

Completed
5 days until next milestone

First Posted

Study publicly available on registry

January 27, 2021

Completed
2.5 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

July 25, 2023

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

July 25, 2023

Completed
Last Updated

August 2, 2023

Status Verified

August 1, 2023

Enrollment Period

2.6 years

First QC Date

January 22, 2021

Last Update Submit

August 1, 2023

Conditions

Complication of Medical CarePneumonia, Viral

Outcome Measures

Primary Outcomes (1)

  • Outcome without comlications

    The recovery time will be evaluated with and without antiviral drugs retrospectively in homogeneous groups of patients with SARS-CoV2

    14 days

Secondary Outcomes (4)

  • Heart rate

    14 days

  • SpO2

    14 days

  • Blood pressure

    14 days

  • Respiratory rate

    14 days

Study Arms (3)

Complications

Evaluathion

Drug: FavipiravirDrug: Remdesivir

Oxygen status

Evaluathion

Drug: FavipiravirDrug: Remdesivir

Oxugen support

Evaluathion

Drug: FavipiravirDrug: Remdesivir

Interventions

FavipiravirDRUG

Antiviral drugs

ComplicationsOxugen supportOxygen status
RemdesivirDRUG

Antiviral drugs

ComplicationsOxugen supportOxygen status

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

patients with previous covid 19 pneumonia

You may qualify if:

  • main group
  • Patients with COVID19 with medium and easy condition disease
  • take favipiravir/remdisivir control group
  • Patients with COVID19 with medium and easy condition disease
  • not take favipiravir/remdisivir

You may not qualify if:

  • patients younger 18
  • severe conditionis

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (2)

Aidos Konkaev

Astana, 010000, Kazakhstan

Location

Semey Medical University

Semey, 071407, Kazakhstan

Location

MeSH Terms

Conditions

Pneumonia, Viral

Interventions

favipiravirremdesivir

Condition Hierarchy (Ancestors)

PneumoniaRespiratory Tract InfectionsInfectionsVirus DiseasesLung DiseasesRespiratory Tract Diseases

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
RETROSPECTIVE
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
doctor

Study Record Dates

First Submitted

January 22, 2021

First Posted

January 27, 2021

Study Start

December 1, 2020

Primary Completion

July 25, 2023

Study Completion

July 25, 2023

Last Updated

August 2, 2023

Record last verified: 2023-08

Data Sharing

IPD Sharing
Will not share

Retrospective study

Locations

KA(2)